Compound Efficacy & VRM

Supporting discovery and pre-clinical compound efficacy

Compound Efficacy Assessment Services

Our hLab offer compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy. We offer compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy.

Includes:

  • Effective concentration 50% (EC50) (TCID50 and plaque reduction) determination for candidate antivirals against Coronavirus alpha and beta (OC43, 229E, SARS-CoV2), RSV A & B and FLU (H3N2 & H1N1) viruses

  • Comparison to medically relevant antiviral compounds available commercially

  • Compound efficacy against hVIVO GMP challenge viruses and a wide range of other relevant related viruses to inform study design

  • Shifts in compound efficacy assessed by EC50 and Next Generation Sequencing (NGS) for phenotypic and genotypic (variant analyses) antiviral resistance monitoring

If you’re a potential customer, job seeker, health professional or an investor, find out how we can help you.

Contact hVIVO

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.
chevron-downarrow-up